Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious and potentially life-threatening conditions involving the skin and mucous membranes. SJS and TEN are considered two ends of the disease spectrum, with SJS being the milder form and TEN being the more severe form. A characteristic feature of these conditions is the separation of the epidermis (the outer layer of the skin) from the dermis (the layer below the skin) due to a strong immune reaction.
Access Full Report @ https://www.databridgemarketresearch.com/reports/global-sjs-ten-treatment-market
Data Bridge Market Research analyzes that the Global SJS/TEN Treatment Market is expected to grow with a CAGR of 7.6% in the forecast period of 2023 to 2030 and is expected to reach USD 12,586.71 million by 2030. The medications segment is projected to propel the market growth as the demand for SJS/TEN treatment is increasing worldwide.
Key Findings of the Study
Developing Effective and Safe Treatments for SJS/TEN Treatment
Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) are serious and potentially life-threatening conditions characterized by detachment and shedding of the outer layer of the skin and mucous membranes. The main cause of SJS/TEN is a drug side effect, although other triggers such as infections and co-morbidities can also play a role. The mortality rate of SJS/TEN can be as high as 30%, and survivors often have long-term complications such as scarring, vision loss, and breathing problems. Therefore, the development of effective and safe SJS/TEN treatments is crucial.
The current standard of care for SJS/TEN is supportive care, including the use of analgesics, wound care, fluid and electrolyte therapy, and infection prevention and treatment. However, there is no consensus on the optimal treatment regimen for SJS/TEN, and the effectiveness of various interventions is largely unclear. Several new treatments have been proposed and tested in recent years, including immunomodulatory therapies, topical agents, and stem cell transplantation.
Thus, the developing effective and safe treatments for SJS/TEN treatment is expected to act as opportunity for the growth of the global SJS/TEN treatment market.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2023 to 2030
|
|
Base Year
|
2022
|
|
Historic Years
|
2021 (Customizable to 2015 - 2020)
|
|
Quantitative Units
|
Revenue in USD Million
|
|
Segments Covered
|
Treatment (Medications, Support Care, Hospitalization, Isolation, Ointments, and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures, and Others), Cause (Specific Treatment, Infection, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult, and Paediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting, and Others), Distribution Channel (Retail Pharmacies, Direct Tender, and Others)
|
|
Countries Covered
|
U.S., Canada, and Mexico, Germany, U.K., France, Italy, Russia, Spain, Netherlands, Denmark, Switzerland, Sweden, Poland, Norway, Finland, Belgium, Turkey, and Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Indonesia, Philippines, Thailand, Malaysia, Singapore, Vietnam, Taiwan, and Rest of Asia-Pacific, Saudi Arabia, South Africa, Bahrain, Kuwait, Oman, Qatar, U.A.E., Egypt, Israel, and Rest of Middle East and Africa, Brazil, Argentina, and Rest of South America
|
|
Market Players Covered
|
3M (U.S.), Cardinal Health (U.S.), BD (U.S.), Smith + Nephew (U.K.), Novartis AG (Switzerland), Amneal Pharmaceuticals LLC. (U.S.), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Colgate-Palmolive Company (U.S.), Merck & Co., Inc. (U.S.), Mölnlycke Health Care AB. (Sweden), Xttrium Laboratories (U.S.), Schülke & Mayr GmbH (Germany), ICPA Health Products Ltd (India), Purdue Pharma L.P. (U.S.), eugia (Subsidiary of Aurobindo Pharma), and AdvaCare Pharma (U.S.) among others
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis and premium insights
|
Segment Analysis:
The global SJS/TEN treatment market is categorized into nine notable segments based on treatment, diagnosis, cause, route of administration, drug type, therapy type, patient type, end user, and distribution channel.
- On the basis of treatment, the global SJS/TEN treatment market is segmented into medications, support care, hospitalization, isolation, ointments, and others. In 2023, the medications segment is expected to dominate the global SJS/TEN treatment market with a 34.50% market share.
In 2023, the medications segment of the treatment segment is expected to dominate the global SJS/TEN treatment market.
- In 2023, the medications segment is expected to dominate due to the growing demand for drugs, such as antihistamines, corticosteroids, analgesics, and others for the treatment of SJS/TEN rare disease.
- On the basis of diagnosis, the global SJS/TEN treatment market is segmented into physical exam, skin biopsy, medical history, blood test, cultures, and others. In 2023, the physical exam segment is expected to dominate the global SJS/TEN treatment market with a 33.73% market share.
In 2023, the physical exam of diagnosis segment is expected to dominate the global SJS/TEN treatment market.
- In 2023, physical exam segment is expected to dominate due to the Increasing awareness about the rare disease SJS/TEN.
- On the basis of cause, the global SJS/TEN treatment market is segmented into specific treatment, infection, and others. In 2023, the specific medication segment is expected to dominate the global SJS/TEN treatment market with a 73.71% market share.
- On the basis of route of administration, the global SJS/TEN treatment market is segmented into oral, parenteral, topical, and others. In 2023, the oral segment is expected to dominate the global SJS/TEN treatment market with a 48.38% market share.
- On the basis of drug type, the global SJS/TEN treatment market is segmented into branded and generic. In 2023, the branded segment is expected to dominate the global SJS/TEN treatment market with a 66.84% market share.
- On the basis of therapy type, the global SJS/TEN treatment market is segmented into combination therapy and monotherapy. In 2023, the combination therapy segment is expected to dominate the global SJS/TEN treatment market with a 64.99% market share.
- On the basis of patient type, the global SJS/TEN treatment market is segmented into geriatric, adult, and pediatric. In 2023, the geriatric segment is expected to dominate the global SJS/TEN treatment market with a 62.25% market share.
- On the basis of end user, the global SJS/TEN treatment market is segmented into hospitals, specialty clinics, ambulatory surgical center, homecare setting, and others. In 2023, the hospitals segment is expected to dominate the global SJS/TEN treatment market with a 53.98% market share.
- On the basis of distribution channel, the global SJS/TEN treatment market is segmented into retail pharmacies, direct tenders, and others. In 2023, the retail pharmacies segment is expected to dominate the global SJS/TEN treatment market with a 63.63% market share.
Major Players
Data Bridge Market Research recognizes the following companies as the major key players operating in the global SJS/TEN treatment market are 3M (U.S.), Cardinal Health (U.S.), BD (U.S.), Smith + Nephew(U.K.), Novartis AG (Switzerland), Amneal Pharmaceuticals LLC. (U.S.), Amgen Inc. (U.S.), Pfizer Inc. (U.S.), Colgate-Palmolive Company (U.S.), Merck & Co., Inc. (U.S.), Mölnlycke Health Care AB. (Sweden), Xttrium Laboratories (U.S.), Schülke & Mayr GmbH (Germany), ICPA Health Products Ltd (India), Purdue Pharma L.P. (U.S.), eugia (Subsidiary of Aurobindo Pharma), AdvaCare Pharma (U.S.) among others.
Market Development
- In April 2023, 3M Health Care's innovative 3M Veraflo Therapy, which includes both the 3M Veraflo Cleanse Choice Complete dressing and the 3M V.A.C. Veraflo Cleanse Choice dressing, the first FDA-approved hydromechanical removal of adhesive material, dead tissue, and wound debris, reduces the number of surgical debridements required and promotes granulation tissue formation, creating an environment conducive to wound healing. This FDA approval highlights 3M innovation at its best – using science to help improve patient outcomes through better, smarter, and safer healthcare solutions. This will help the company to grow and create a good image in the market.
- In July 2022, Smith+Nephew, the global medical technology company, launched a clinical support app to help reduce practice variation in wound care. The wound compass clinical support app is a comprehensive digital support tool for healthcare professionals that aids wound assessment and decision-making to help reduce practice variation. This has helped the company to attract healthcare customers and expand its product portfolio. This will help the company to expand and grow in the market.
- In June 2020, BD, a leading global medical technology company announced that they have completed the acquisition of Straub Medical AG, a privately-held company. With this acquisition, the company has added the valuable expertise and experience of Straub Medical AG and expanded its product portfolio. This will help the company to expand and grow in the market.
- In January 2019, Mölnlycke Health Care AB. acquires MandJ Airlaid Products A/S to further strengthen its wound care capabilities. In connection with the acquisition, MandJ, and its employees will be an integral part of Mölnlycke. The acquisition will improve Mölnlycke's security of supply for the air-laid material needed to produce advanced wound dressings and help grow the wound care business by accelerating innovation and product development in existing and future products. This will help the company to expand and grow in the market.
Regional Analysis
Geographically, the countries covered in the global SJS/TEN treatment market report are U.S., Canada, Mexico, Germany, U.K., France, Italy, Russia, Spain, Netherlands, Denmark, Switzerland, Sweden, Poland, Norway, Finland, Belgium, Turkey, Rest of Europe, China, Japan, India, New Zealand, Australia, South Korea, Indonesia, Philippines, Thailand, Malaysia, Singapore, Vietnam, Taiwan, Rest of Asia-Pacific, Saudi Arabia, South Africa, Bahrain, Kuwait, Oman, Qatar, U.A.E., Egypt, Israel, and Rest of Middle East and Africa, Brazil, Argentina, Rest of South America. As per Data Bridge Market Research analysis:
Asia-Pacific is the dominant region in the global SJS/TEN treatments market during the forecast period 2023-2030
In 2023, Asia-Pacific dominated the SJS/TEN treatment market owing to the higher level of investments by manufacturers and increasing incidence of SJS/TEN in the region and due to the growing adoption of advanced technology and launch of new imaging technology in this region. Additionally, the increasing demand for SJS/TEN treatment and advancement in the industries are expected to further enhance the market's growth rate in this region.
Asia-Pacific is estimated to be the fastest growing region in the global SJS/TEN treatments market for the forecast period 2023-2030
Asia-Pacific is expected to grow during the forecast period due to the presence of major market players and rapid development in healthcare industries in this region. In addition to this, rising strategic initiatives by major market players in the region is expected to propel the market's growth rate in this region.
For more detailed information about the global SJS/TEN treatment market report, click here – https://www.databridgemarketresearch.com/reports/global-sjs-ten-treatment-market
